The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.

An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.